Hypersensitivity eosinophilic myocarditis possibly triggered by meglumine antimoniate

Hypersensitivity eosinophilic myocarditis possibly triggered by meglumine antimoniate

Bibliographic Details
Main Authors:	Sergio A. Bolivar-Lozano, Leidy J. Medina-Lozano, Merardo Andrés Vega Báez, Diego A. Vargas-Hernández, Oscar Galves, Ana Catalina Herrera, Álvaro A. Faccini-Martínez
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	Travel Medicine and Infectious Disease
Subjects:	Hypereosinophilic syndrome Myocarditis Meglumine antimoniate Leishmaniasis Colombia
Online Access:	http://www.sciencedirect.com/science/article/pii/S1477893924000024

Similar Items

Comparison of Intralesional Meglumine Antimoniate Plus Oral Allopurinol with Intralesional Meglumine Antimoniate Alone for the Treatment of Cutaneous Leishmaniasis- A Prospective Study
by: Nida Qayyum, et al.
Published: (2024-05-01)

Treatment of cutaneous leishmaniasis with combination of allopurinol and low dose of meglumine antimoniate
by: A Momeni, et al.
Published: (2001-03-01)

Treatment of Canine Leishmaniasis with Meglumine Antimoniate: A Clinical Study of Tolerability and Efficacy
by: Serena Digiaro, et al.
Published: (2024-08-01)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
by: Erica de Camargo Ferreira e Vasconcellos, et al.
Published: (2014-07-01)

Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities
by: Maria Inês Fernandes Pimentel, et al.

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
by: Cláudia Maria Valete-Rosalino, et al.
Published: (2014-09-01)

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
by: Rosiana Estéfane da Silva, et al.
Published: (2016-08-01)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
by: Dario Brock Ramalho, et al.
Published: (2018-06-01)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Marcelo Rosandiski LYRA, et al.

Pentavalent Antimonials: New Perspectives for Old Drugs
by: Raul R. Ribeiro, et al.
Published: (2009-06-01)

Warning against increasing cases of cutaneous leishmaniasis and unavailability of meglumine in Pakistan
by: Sadia Iram, et al.
Published: (2023-12-01)

In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L (L.) chagasi and L (Viannia) braziliensis
by: Eliane de Morais-Teixeira, et al.
Published: (2008-06-01)

Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
by: Lucia Regina Brahim, et al.

Eosinophilic Myocarditis in Hypereosinophilic Syndrome
by: Rui Assis, et al.
Published: (2020-01-01)

NEPHROTOXICITY ATTRIBUTED TO MEGLUMINE ANTIMONIATE (GLUCANTIME) IN THE TREATMENT OF GENERALIZED CUTANEOUS LEISHMANIASIS
by: M.L.O. RODRIGUES, et al.
Published: (1999-01-01)

The Efficacy of Intralesional Meglumine Antimoniate (Glucantime) versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions
by: Mohammad Ali Nilforoushzadeh, et al.
Published: (2011-12-01)

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol
by: Laura Manna, et al.
Published: (2015-05-01)

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
by: Rosiana Estéfane da Silva, et al.

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
by: Diana Berenguer, et al.
Published: (2019-11-01)

Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask
by: Sayed Abolfazl Mostafavi, et al.
Published: (2013-06-01)

Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis
by: Juliana Figueiredo Peixoto, et al.
Published: (2024-04-01)

Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions
by: Jamyra Iglesias Cataldo, et al.

Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity
by: Samanta Etel Treiger Borborema, et al.
Published: (2016-04-01)

Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice
by: Samanta Etel Treiger Borborema, et al.
Published: (2013-08-01)

The Efficacy of Carbon Dioxide Laser in the Treatment of Chronic and Lupoid Cutaneous Leishmaniasis in Kerman City: A Randomized Clinical Trial
by: I Esfandiarpour, et al.
Published: (2014-07-01)

<i>In Vivo</i> Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment
by: Atteneri López-Arencibia, et al.
Published: (2024-08-01)

Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
by: Maria del Mar Castro, et al.
Published: (2022-03-01)

The Additive Effect of Topical Ciprofloxacin 2% on Intralesional Glucantime Injection in Treatment of Cutaneous Leishmaniasis
by: Mohamadjavad Yazdanpanah, et al.
Published: (2020-06-01)

Mucosal leishmaniasis: the experience of a Brazilian referral center
by: Mariana Junqueira Pedras, et al.

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Madelon Novato Ribeiro, et al.
Published: (2014-07-01)

Critically Appraised Topic on Canine Leishmaniosis: Does Treatment with Antimonials and Allopurinol Have the Same Clinical and Clinicopathological Efficacy as Treatment with Miltefosine and Allopurinol, after One Month of Treatment?
by: Marina García, et al.
Published: (2024-05-01)

A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis
by: Raimunda Nonata Ribeiro Sampaio, et al.
Published: (2019-03-01)

Myocarditis with neurological and dermatological involvement in idiopathic Hypereosinophilic syndrome: Case report
by: Merimi Ihssane, et al.
Published: (2025-03-01)

Meglumine Antimoniate and Miltefosine Combined With Allopurinol Sustain Pro-inflammatory Immune Environments During Canine Leishmaniosis Treatment
by: Marcos Ferreira Santos, et al.
Published: (2019-10-01)

Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis
by: Michal Solomon, et al.
Published: (2024-04-01)

Effects of Meglumine Antimoniate Treatment on Cytokine Production in a Patient with Mucosal Leishmaniasis and Chagas Diseases Co-Infection
by: Karine Rezende-Oliveira, et al.
Published: (2020-05-01)

Estudo comparativo entre estibogluconato de sódio BP 88® e antimoniato de meglumina no tratamento da leishmaniose cutânea II. Toxicidade bioquímica e cardíaca Comparative study between sodium stibogluconate BP 88®and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity
by: Ana Cristina R. Saldanha, et al.
Published: (2000-08-01)

Eosinophilic myocarditis: Case report and brief review of the literature
by: Thomas Fakadej, BS, et al.
Published: (2023-01-01)

Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania (Viannia) braziliensis</i>
by: Carvel Suprien, et al.
Published: (2024-04-01)

Refractory Idiopathic Hypereosinophilic Syndrome Presenting with Myocarditis and Responding to Imatinib: A Case Report
by: Rasha Ali Albayyat, et al.
Published: (2025-01-01)